AstraZeneca-AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform

Key Takeaways AstraZeneca's (AZN) second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks Consensus Estimate. Core earnings of$ 2.17 per share rose 10% year over year on a reported basis and 12% on a constant exchange rate (CER). Total revenues of $14.46 billion rose 12% on a reported basis and 11% at CER, driven by higher product sales and alliance revenues from partnered medicines. Revenues beat the Zacks Consensus Estimate of$ 14.03 billion. All growth r ...